Cargando…

Bcl10 mutations in malignancy

Detalles Bibliográficos
Autor principal:	Dyer, M J S
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1999
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363161/ https://www.ncbi.nlm.nih.gov/pubmed/10408386 http://dx.doi.org/10.1038/sj.bjc.6690549

Ejemplares similares

Immunodeficiency and CARD-BCL10-MALT1
por: Pérez de Diego, Rebeca
Publicado: (2015)

Mutations in Bcl10 are very rare in colorectal cancer
por: Stone, J G, et al.
Publicado: (1999)

Bcl10 is not a target for frequent mutation in human carcinomas
por: Lambers, A R, et al.
Publicado: (1999)

BCL10 is rarely mutated in human prostate carcinoma, small-cell lung cancer, head and neck tumours, renal carcinoma and sarcomas
por: Gill, S, et al.
Publicado: (1999)

Role of the CARMA1/BCL10/MALT1 complex in lymphoid malignancies
por: Juilland, Mélanie, et al.
Publicado: (2016)

Infrequent BCL10 Mutations in B‐Cell Non‐Hodgkin's Lymphomas
por: Takahashi, Hidenobu, et al.
Publicado: (1999)

BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL
por: Xia, Min, et al.
Publicado: (2022)

Lack of Bcl10 mutations in testicular germ cell tumours and derived cell lines
por: Schothorst, E M van, et al.
Publicado: (1999)

Bcl-G acquitted of murder!
por: Tischner, D, et al.
Publicado: (2012)

Targeting Bcl2 in cancer
por: Chen, Guo, et al.
Publicado: (2015)

Cohesin mutations: contributors to myeloid malignancies
por: Meyer, Alison E., et al.
Publicado: (2017)

The prognostic influence of bcl-2 in malignant glioma
por: McDonald, F E, et al.
Publicado: (2002)

BCL-2 proteins: melanoma lives on the edge
por: Chipuk, Jerry Edward
Publicado: (2015)

The epigenetic regulator CTCF modulates BCL6 in lymphoma
por: Batlle-López, Ana, et al.
Publicado: (2015)

Antagonizing Bcl-2′s BH4 domain in cancer
por: Vervloessem, Tamara, et al.
Publicado: (2015)

Advances in Bcl-xL Research 2.0
por: Kervadec, Joann, et al.
Publicado: (2023)

The role of BCL11B in hematological malignancy
por: Huang, Xin, et al.
Publicado: (2012)

BCL-2 as therapeutic target for hematological malignancies
por: Perini, Guilherme Fleury, et al.
Publicado: (2018)

The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL
por: Kampen, Kim R., et al.
Publicado: (2018)

BCL10 – Bridging CARDs to Immune Activation
por: Gehring, Torben, et al.
Publicado: (2018)

Clinical and Immunological Features of Human BCL10 Deficiency
por: Garcia-Solis, Blanca, et al.
Publicado: (2021)

BCL-XL is an actionable target for treatment of malignant pleural mesothelioma
por: Arulananda, Surein, et al.
Publicado: (2020)

Bcl-xL inhibition - a novel strategy for glioma therapy
por: Karpel-Massler, Georg, et al.
Publicado: (2016)

Regulation of Apoptosis by the Bcl-2 Family of Proteins: Field on a Brink
por: Ladokhin, Alexey S.
Publicado: (2020)

Roles and Regulation of BCL-xL in Hematological Malignancies
por: Morales-Martínez, Mario, et al.
Publicado: (2022)

BCL10-CARD11 Fusion Mimics an Active CARD11 Seed That Triggers Constitutive BCL10 Oligomerization and Lymphocyte Activation
por: Seeholzer, Thomas, et al.
Publicado: (2018)

Correction: The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL
por: Kampen, Kim R., et al.
Publicado: (2019)

Coordinate PI3K pathway and Bcl-2 family disruption in AML
por: Bose, Prithviraj, et al.
Publicado: (2012)

Structural Insights into the Assembly of CARMA1 and BCL10
por: Li, Siwei, et al.
Publicado: (2012)

Functional Characterization of Zebrafish (Danio rerio) Bcl10
por: Mazzone, Pellegrino, et al.
Publicado: (2015)

The Role of Bcl-2 Family Proteins in Therapy Responses of Malignant Astrocytic Gliomas: Bcl2L12 and Beyond
por: Kouri, Fotini M., et al.
Publicado: (2012)

Preventive Properties of Ramelteon against Cocaine-Induced Autophagia and Apoptosis: A Hypothetic Role of TNF-α Receptor Involvement and JNK/Bcl-2-Beclin1 or Bcl-2/Bax Signaling Pathway
por: Kandezi, Niyoosha, et al.
Publicado: (2020)

Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma
por: Arulananda, Surein, et al.
Publicado: (2021)

Alternative splicing of BCL-X and implications for treating hematological malignancies
por: Chen, Wanling, et al.
Publicado: (2021)

Targeting BCL6 and STAT3 in triple negative breast cancer: the one-two punch?
por: Walker, Sarah R., et al.
Publicado: (2015)

BFL-1 expression determines the efficacy of venetoclax in MYC+/BCL2+ double hit lymphoma
por: Esteve-Arenys, Anna, et al.
Publicado: (2018)

BH4-mimetics and -antagonists: an emerging class of Bcl-2 protein modulators for cancer therapy
por: Nougarède, Adrien, et al.
Publicado: (2018)

Molecular architecture and regulation of BCL10-MALT1 filaments
por: Schlauderer, Florian, et al.
Publicado: (2018)

IRBIT controls apoptosis by interacting with the Bcl-2 homolog, Bcl2l10, and by promoting ER-mitochondria contact
por: Bonneau, Benjamin, et al.
Publicado: (2016)

Mcl‐1 and Bcl‐xL levels predict responsiveness to dual MEK/Bcl‐2 inhibition in B‐cell malignancies
por: Melvold, Katrine, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uepsbuedengt9m3llh2ka2c75q